Countries covered: Czech Republic
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts.
Please note: This is delivered as a Zip file.
Additional Information
The Czech Republic was one of the larger countries to join the EU in May 2004. The Czech market for pharmaceuticals was the third largest in the region in 2009, worth an estimated US$4,234 million, or US$415 per capita. It is expected that the pharmaceutical market will continue to expand at a CAGR of 9.6% per annum, taking it to US$6,689 million, or US$660 per capita by 2014.
Local production of generics is strong, and was enhanced in 2003 by the merger of the leading Czech manufacturer, Leciva, with its Slovak counterpart, Slovakofarma, to form Zentiva. The company boosted its sales growth in July 2007 with the acquisition of Turkey’s Eczacibaºi Generic Pharmaceuticals. There is little branded manufacturing in the Czech Republic. It is easily reached from other EU countries such as Germany or Austria, and the market is increasingly dominated by imported products.
The country has a history of high drug consumption, a legacy of many years of reliance on cheap generics. In January 2008, the government introduced new fees for prescriptions and visits to the doctor that could result in reduced pharmaceutical sales. The opposition argues that the fees violate the law which guarantees medical care for every citizen. People aged under 18 years are now exempt from the fees.
Healthcare funding is largely public, through health insurance. Provision of care is also largely public; the Czech Republic has yet to develop a substantial private sector. Private spending only accounts for around 12.1% of the total in 2009. One of the reasons for the new fees introduced in 2008 was to increase funding for the healthcare system.
One major concern of EU entry was that branded drugs priced cheaply on the Czech market would be parallel exported to high-price EU markets such as Germany or the UK. The accession treaties for the new entrant countries in 2004 specifically prevented this, however, as long as the drug in question has a patent in the target market.
Related Reports:
Snapshots US Pharmaceuticals 2009
Mapping the Healthcare Landscape Bringing pharmaceuticals into focus
Snapshots Hungary Pharmaceuticals 2009
Snapshots Venezuela Pharmaceuticals 2009
Snapshots Spain Pharmaceuticals 2009
Snapshots Poland Pharmaceuticals 2009
Snapshots South Africa Pharmaceuticals 2009
Poland Pharmaceuticals and Healthcare Report Q1 2010
Australia Pharmaceuticals and Healthcare Report Q1 2010
Nigeria Pharmaceuticals and Healthcare Report Q1 2010
|
(0 items)
